NASDAQ:ANAB - AnaptysBio Stock Price, Forecast & News

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio Inc (NASDAQ:ANAB) released its quarterly earnings data on Friday, November, 8th. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.09) by $0.06. During the same period in the prior year, the business earned ($0.66) earnings per share. View AnaptysBio's Earnings History.

AnaptysBio is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AnaptysBio.

9 Wall Street analysts have issued 12-month price objectives for AnaptysBio's stock. Their forecasts range from $12.00 to $140.00. On average, they anticipate AnaptysBio's stock price to reach $79.25 in the next twelve months. This suggests a possible upside of 401.6% from the stock's current price. View Analyst Price Targets for AnaptysBio.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AnaptysBio.

News stories about ANAB stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AnaptysBio earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the near future. View News Stories for AnaptysBio.

AnaptysBio saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 4,420,000 shares, an increase of 11.3% from the January 15th total of 3,970,000 shares. Based on an average daily volume of 999,800 shares, the days-to-cover ratio is presently 4.4 days. Currently, 18.1% of the shares of the company are short sold. View AnaptysBio's Current Options Chain.

Some companies that are related to AnaptysBio include PPD (SDGR), Alder Biopharmaceuticals (ALDR), TG Therapeutics (TGTX), Innoviva (INVA), Corcept Therapeutics (CORT), ZEALAND PHARMA/S (ZEAL), Constellation Pharmaceuticals (CNST), Amneal Pharmaceuticals (AMRX), Nabriva Therapeutics (NBRV), Dicerna Pharmaceuticals (DRNA), Zogenix (ZGNX), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Madrigal Pharmaceuticals (MDGL) and Endo International (ENDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Alibaba Group (BABA), Baidu (BIDU), Baozun (BZUN), Momo (MOMO), AbbVie (ABBV), Crispr Therapeutics (CRSP), ImmunoGen (IMGN) and IQIYI (IQ).

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (7.17%), Tang Capital Management LLC (6.80%), Boxer Capital LLC (4.79%), Perceptive Advisors LLC (3.69%), BVF Inc. IL (3.46%) and Krensavage Asset Management LLC (1.62%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria, Marco Londei and Nicholas Lydon. View Institutional Ownership Trends for AnaptysBio.

ANAB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and SG Americas Securities LLC. Company insiders that have sold AnaptysBio company stock in the last year include Hamza Suria and Marco Londei. View Insider Buying and Selling for AnaptysBio.

ANAB stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Boxer Capital LLC, Perceptive Advisors LLC, State Street Corp, BVF Inc. IL, Krensavage Asset Management LLC, Broadfin Capital LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for AnaptysBio.

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANAB stock can currently be purchased for approximately $15.80.

AnaptysBio has a market capitalization of $428.65 million and generates $5 million in revenue each year. The biotechnology company earns $-61,660,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.View Additional Information About AnaptysBio.

The official website for AnaptysBio is http://www.anaptysbio.com/.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]